Research programme: Nanobodies - Ablynx/Sanofi Genzyme

Drug Profile

Research programme: Nanobodies - Ablynx/Sanofi Genzyme

Latest Information Update: 16 Dec 2016

Price : $50

At a glance

  • Originator Ablynx; Genzyme Corporation
  • Developer Ablynx; Sanofi Genzyme
  • Class Proteins
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Multiple sclerosis

Most Recent Events

  • 18 May 2015 Ablynx and Genzyme enters into research collaboration for the development of Nanobodies®-based therapeutics for the treatment of Multiple sclerosis
  • 18 May 2015 Preclinical trials in Multiple sclerosis in Belgium and USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top